NVO•benzinga•
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
Summary
Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 11, 2025 by benzinga